FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090532253> ?p ?o ?g. }

• W2090532253 endingPage "e0119683" @default.
• W2090532253 startingPage "e0119683" @default.
• W2090532253 abstract "Background and Objectives Economic evaluations provide information to aid the optimal utilization of limited healthcare resources. Costs of biologics for Rheumatoid arthritis (RA) are remarkably high, which makes these agents an important target for economic evaluations. This systematic review aims to identify existing studies examining the cost-effectiveness of biologics for RA, assess their quality and report their results systematically. Methods A literature search covering Medline, Scopus, Cochrane library, ACP Journal club and Web of Science was performed in March 2013. The cost-utility analyses (CUAs) of one or more available biological drugs for the treatment of RA in adults were included. Two independent investigators systematically collected information and assessed the quality of the studies. To enable the comparison of the results, all costs were converted to 2013 euro. Results Of the 4890 references found in the literature search, 41 CUAs were included in the current systematic review. While considering only direct costs, the incremental cost-effectiveness ratio (ICER) of the tumor necrosis factor inhibitors (TNFi) ranged from 39,000 to 1 273,000 €/quality adjusted life year (QALY) gained in comparison to conventional disease-modifying antirheumatic drugs (cDMARDs) in cDMARD naïve patients. Among patients with an insufficient response to cDMARDs, biologics were associated with ICERs ranging from 12,000 to 708,000 €/QALY. Rituximab was found to be the most cost-effective alternative compared to other biologics among the patients with an insufficient response to TNFi. Conclusions When 35,000 €/QALY is considered as a threshold for the ICER, TNFis do not seem to be cost-effective among cDMARD naïve patients and patients with an insufficient response to cDMARDs. With thresholds of 50,000 to 100,000 €/QALY biologics might be cost-effective among patients with an inadequate response to cDMARDs. Standardization of multiattribute utility instruments and a validated standard conversion method for missing utility measures would enable better comparison between CUAs." @default.
• W2090532253 created "2016-06-24" @default.
• W2090532253 creator A5037971892 @default.
• W2090532253 creator A5046670167 @default.
• W2090532253 creator A5047503586 @default.
• W2090532253 creator A5048402348 @default.
• W2090532253 creator A5050963625 @default.
• W2090532253 creator A5072549740 @default.
• W2090532253 date "2015-03-17" @default.
• W2090532253 modified "2023-10-17" @default.
• W2090532253 title "The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review" @default.
• W2090532253 cites W1551539224 @default.
• W2090532253 cites W1593173821 @default.
• W2090532253 cites W1743222759 @default.
• W2090532253 cites W1911407202 @default.
• W2090532253 cites W1967020676 @default.
• W2090532253 cites W1981122966 @default.
• W2090532253 cites W1984009427 @default.
• W2090532253 cites W1987798158 @default.
• W2090532253 cites W1988152642 @default.
• W2090532253 cites W1989781627 @default.
• W2090532253 cites W1991000304 @default.
• W2090532253 cites W1999306257 @default.
• W2090532253 cites W2002814457 @default.
• W2090532253 cites W2014937111 @default.
• W2090532253 cites W2016963118 @default.
• W2090532253 cites W2020049366 @default.
• W2090532253 cites W2020515680 @default.
• W2090532253 cites W2037010889 @default.
• W2090532253 cites W2040686340 @default.
• W2090532253 cites W2085318733 @default.
• W2090532253 cites W2085700353 @default.
• W2090532253 cites W2088483534 @default.
• W2090532253 cites W2097226281 @default.
• W2090532253 cites W2097553517 @default.
• W2090532253 cites W2097585904 @default.
• W2090532253 cites W2102987799 @default.
• W2090532253 cites W2103853363 @default.
• W2090532253 cites W2113546241 @default.
• W2090532253 cites W2113633952 @default.
• W2090532253 cites W2118420318 @default.
• W2090532253 cites W2119138901 @default.
• W2090532253 cites W2120393706 @default.
• W2090532253 cites W2120523887 @default.
• W2090532253 cites W2124360207 @default.
• W2090532253 cites W2127622911 @default.
• W2090532253 cites W2129929473 @default.
• W2090532253 cites W2131211229 @default.
• W2090532253 cites W2133038175 @default.
• W2090532253 cites W2134363311 @default.
• W2090532253 cites W2142704172 @default.
• W2090532253 cites W2143690407 @default.
• W2090532253 cites W2148951322 @default.
• W2090532253 cites W2149338618 @default.
• W2090532253 cites W2150049088 @default.
• W2090532253 cites W2150157851 @default.
• W2090532253 cites W2162254515 @default.
• W2090532253 cites W2166697744 @default.
• W2090532253 cites W2168250184 @default.
• W2090532253 cites W2171202266 @default.
• W2090532253 cites W2278975836 @default.
• W2090532253 cites W2752280857 @default.
• W2090532253 cites W4210768724 @default.
• W2090532253 cites W4246803526 @default.
• W2090532253 doi "https://doi.org/10.1371/journal.pone.0119683" @default.
• W2090532253 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4363598" @default.
• W2090532253 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25781999" @default.
• W2090532253 hasPublicationYear "2015" @default.
• W2090532253 type Work @default.
• W2090532253 sameAs 2090532253 @default.
• W2090532253 citedByCount "74" @default.
• W2090532253 countsByYear W20905322532015 @default.
• W2090532253 countsByYear W20905322532016 @default.
• W2090532253 countsByYear W20905322532017 @default.
• W2090532253 countsByYear W20905322532018 @default.
• W2090532253 countsByYear W20905322532019 @default.
• W2090532253 countsByYear W20905322532020 @default.
• W2090532253 countsByYear W20905322532021 @default.
• W2090532253 countsByYear W20905322532022 @default.
• W2090532253 countsByYear W20905322532023 @default.
• W2090532253 crossrefType "journal-article" @default.
• W2090532253 hasAuthorship W2090532253A5037971892 @default.
• W2090532253 hasAuthorship W2090532253A5046670167 @default.
• W2090532253 hasAuthorship W2090532253A5047503586 @default.
• W2090532253 hasAuthorship W2090532253A5048402348 @default.
• W2090532253 hasAuthorship W2090532253A5050963625 @default.
• W2090532253 hasAuthorship W2090532253A5072549740 @default.
• W2090532253 hasBestOaLocation W20905322531 @default.
• W2090532253 hasConcept C112930515 @default.
• W2090532253 hasConcept C126322002 @default.
• W2090532253 hasConcept C17744445 @default.
• W2090532253 hasConcept C177713679 @default.
• W2090532253 hasConcept C1862650 @default.
• W2090532253 hasConcept C189708586 @default.
• W2090532253 hasConcept C199539241 @default.
• W2090532253 hasConcept C2776478404 @default.
• W2090532253 hasConcept C2777575956 @default.
• W2090532253 hasConcept C2779338263 @default.

• next